Vincerx Pharma, Inc.
Vincerx Pharma, Inc. (VINC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
vinc · stock forecast · 7 analysts (3M) · FMP · updated May 30, 2026
Analyst Rating & Consensus
Based on 7 Wall Street analysts in the past 3 months
Buy
7 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$4.00
Consensus
$3.00
+22713.7% upside
Low
$2.00
Median: $3 · Last Close: $0.01
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.01 | ↓ 2.24% |
1-day model range: $0.01–$0.01. Peak: $0.01 (-2.24%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · VINC · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2024-10-08 | Leerink Partners | Maintains | Outperform→Outperform |
| 2023-09-07 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2022-11-17 | Chardan Capital | Maintains | Buy→Buy |
| 2022-08-12 | SVB Leerink | Maintains | Outperform→Outperform |
| 2022-06-08 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2022-06-07 | Chardan Capital | Maintains | Buy→Buy |
| 2022-06-07 | B. Riley Securities | Maintains | Buy→Buy |
| 2022-06-07 | SVB Leerink | Maintains | Outperform→Outperform |
| 2022-05-13 | Chardan Capital | Maintains | Buy→Buy |
| 2022-05-13 | SVB Leerink | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Vincerx Pharma, Inc. (VINC) stock. Of the recent 19 rating actions, 0 were upgrades and 0 were downgrades. 7 analysts currently cover VINC.
Analyst Recommendation Trends
VINC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$18M
EPS This Year
$-15.60
EPS Next Year
$-12.00
↓ 23.1% YoY
EPS ForecastReported vs Estimated
Analysts forecast VINC EPS of $-15.60 for the current fiscal year, based on estimates from 1 analysts. The VINC revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The VINC stock forecast is supported by two independent data sources: analyst consensus ratings from 7 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus VINC price target is $3.00 (+22713.7% upside), with an analyst consensus of Buy.
The VINC short-term stock prediction for tomorrow is $0.01 (-2.24%).
Vincerx Pharma, Inc. trades on OTC under the ticker VINC. The VINC stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
VINC forecast · 8 questionsAccording to 7 Wall Street analysts, the average 12-month VINC price target is $3.00, with a high forecast of $4.00 and a low of $2.00. The median price target is shown in the chart above when available. This implies +22713.7% potential upside from the current price of $0.01.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.